Stocks Screener

Specify Company / Ticker to Get the Summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Adagene Inc

ADAG
Current price
2.06 USD -0.16 USD (-7.21%)
Last closed 2.15 USD
ISIN US0053291078
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 108 463 464 USD
Yield for 12 month +9.57 %
1Y
3Y
5Y
10Y
15Y
ADAG
21.11.2021 - 28.11.2021

Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company's product candidates include ADG106, a human ligand-blocking agonistic anti- CD137 IgG4 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a masked fully-human anti-CTLA-4 mAb that is in Phase 1 clinical trial for the treatment advanced/metastatic solid tumors; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase 1b/2 clinical development for the treatment of advanced/metastatic solid tumors. It also offers ADG104, an anti-PD-L1 mAb that is in Phase 2 clinical development; ADG125, a novel anti-CSF-1R mAb, which is in Phase I clinical trial; ADG206, a masked, Fc engineered anti-CD137 agonistic POWERbody; ADG153, a masked anti-CD47 IgG1 SAFEbody, which is in preclinical for the treatment hematologic and solid tumors; ADG138, novel HER2xCD3 POWERbody, which is in preclinical for the treatment HER2-expressing solid tumors; and ADG152, a v POWERbody, which is in preclinical stage for the treatment off-tumor toxicities, as well as develops anti-CD28 bispecific POWERbody TCEs. The company was incorporated in 2011 and is headquartered in Suzhou, China. Address: Building C14, Suzhou, China, 215123

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

10.54 USD

P/E ratio

Dividend Yield

Current Year

+18 111 491 USD

Last Year

+9 292 724 USD

Current Quarter

Last Quarter

Current Year

+18 111 491 USD

Last Year

+9 292 724 USD

Current Quarter

Last Quarter

Key Figures ADAG

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -36 131 064 USD
Operating Margin TTM -4534.83 %
PE Ratio
Return On Assets TTM -19.59 %
PEG Ratio
Return On Equity TTM -45.7 %
Wall Street Target Price 10.54 USD
Revenue TTM 815 746 USD
Book Value 1.28 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY -84.8 %
Dividend Yield
Gross Profit TTM 10 175 258 USD
Earnings per share -0.72 USD
Diluted Eps TTM -0.72 USD
Most Recent Quarter III 2024
Quarterly Earnings Growth YOY
Profit Margin

Dividend Analytics ADAG

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History ADAG

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor
Payout Ratio
Last Split Date
Dividend Date

Stock Valuation ADAG

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 27.0547
Price Sales TTM 118.852
Enterprise Value EBITDA 1.1206
Price Book MRQ 1.7133

Financials ADAG

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators ADAG

For 52 weeks

1.35 USD 4.38 USD
50 Day MA 2.62 USD
Shares Short Prior Month 12 294
200 Day MA 2.76 USD
Short Ratio 0.33
Shares Short 1 514
Short Percent 0.03 %